FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

BREITMEYER JAMES B							CADENCE PHARMACEUTICALS INC [CADX]									chick all applicable) Director Officer (give title below)		10% Ov Other (s	vner	
(Last) (First) (Middle) C/O CADENCE PHARMACEUTICALS, INC. 12481 HIGH BLUFF DRIVE, SUITE 200						3. Date of Earliest Transaction (Month/Day/Year) 02/03/2011										EVP, CMO				
(Street) SAN DII			92130 (Zip)		_ 4. l	4. If Amendment, Date of Original Filed (Month/Day/Year)									dividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - No	on-Deri	vative	e Se	curit	ies Ac	quired	l, Di	sposed o	f, or Be	neficia	lly Ov	vned	l				
Date				2. Transa Date (Month/D		r) E	2A. Deemed Execution Date, if any (Month/Day/Year)					4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 a					6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										v	Amount	(A) or (D)	Price	Transac (Instr. 3		ction(s)			(111341. 4)	
common	stock			02/03	/2011				М		39,000	A	\$3.2	2	49,000 D					
common	stock			02/03	/2011				S ⁽¹⁾		39,000	D	\$7.38	5(2)	10,	,000	00 D			
		7	Гable II								oosed of, convertil			y Owi	ned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deen Executio if any (Month/D	n Date,	Code (Ir				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owr Forn Dire or Ir (I) (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares	r						
stock option (right to	\$3.2	02/03/2011			M			39,000	08/14/2	2006	08/13/2016	common	39,000	(3	3)	90,250)	D		

Explanation of Responses:

- 1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2010.
- 2. This transaction was executed in multiple trades at prices ranging from a low of \$7.24 to a high of \$7.45. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 3. Not applicable to this transaction

Remarks:

buy)

Hazel M. Aker Attorney-in-fact 02/04/2011

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.